BAT 6024
Alternative Names: BAT-6024Latest Information Update: 28 Jun 2022
At a glance
- Originator Bio-Thera Solutions
- Class Antihyperlipidaemics; Bispecific antibodies
- Mechanism of Action ANGPTL3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Hypertriglyceridaemia
Highest Development Phases
- Preclinical Hypertriglyceridaemia
Most Recent Events
- 28 Jun 2022 BAT 6024 is available for licensing as of 28 Jun 2022. https://www.bio-thera.com/plus/list.php?tid=42